Zurcher Kantonalbank Zurich Cantonalbank Purchases 21,102 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 60.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,298 shares of the company’s stock after acquiring an additional 21,102 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Sana Biotechnology were worth $95,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its position in shares of Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after acquiring an additional 10,548 shares during the period. Cerity Partners LLC bought a new stake in Sana Biotechnology during the fourth quarter valued at approximately $25,000. Syon Capital LLC bought a new stake in Sana Biotechnology during the fourth quarter valued at approximately $27,000. Pallas Capital Advisors LLC bought a new stake in Sana Biotechnology during the first quarter valued at approximately $29,000. Finally, Ameriprise Financial Inc. bought a new stake in Sana Biotechnology during the fourth quarter valued at approximately $29,000. 88.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on SANA shares. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday, June 24th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Sana Biotechnology in a research report on Thursday, April 24th. Finally, Morgan Stanley started coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $8.00.

Sana Biotechnology Stock Performance

Shares of SANA opened at $3.00 on Monday. The firm has a market cap of $676.43 million, a price-to-earnings ratio of -3.41 and a beta of 1.90. Sana Biotechnology, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The firm has a 50 day moving average price of $3.49 and a 200-day moving average price of $2.69.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. As a group, equities research analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.